The chair of Proteomics and Bioanalytics at the Technical University of Munich comprises an international research team with a focus on proteomics and chemical biology.

Most of our research builds on the powerful combination of cell biology, chemistry, biochemistry, mass spectrometry and bioinformatics. We develop novel analytical methods for quantitative proteome research notably for high throughput applications and  the analysis of post translational protein modifications (PTMs). In our chemical biology efforts, we elucidate the selectivity of drug-target interactions on a proteome-wide scale, investigate the cellular mechanisms by which drugs exert their function and identify mechanisms of cancer therapy resistance. In addition, we investigate phosphoproteomic signaling events as biomarkers for patient stratification, as well as indicators of drug effectiveness and treatment response. Our bioinformatic flagship project is ProteomicsDB that offers open access to data analytics on large-scale proteomics and transcriptomics projects.

Since its inception in September 2007, the group is led by Bernhard Küster who coordinates the CLINSPECT-M consortium (translation of mass spectrometry based proteomics into a clinical setting), the DIAS (data integration, analytics and services in ProteomicsDB) and the ProteomeTools project. Bernhard Küster is a principle investigator of the German Cancer Consortium DKTK and the Collaborative Research Center SFB 924 (molecular mechanisms regulating yield and yield stability in plants), SFB 1309 (chemical biology of epigenetic modifications) and SFB 1321 (modeling and targeting pancratic cancer). In 2019, he was awarded an ERC advanced grant ("Exploiting the Tumor Proteome Activity Status for Future Cancer Therapies"). He also co-directs the Bavarian Biomolecular Mass Spectrometry Center BayBioMS.